New Brunswick Drugs for Rare Diseases Plan
The New Brunswick Drugs for Rare Diseases Plan provides assistance with the cost of certain drugs for specific rare diseases
Individuals must be a permanent resident of New Brunswick and have a valid Medicare card.
A request form for a listed drug must be completed by the physician and the individual must meet the clinical criteria for the drug requested.
New Brunswick partners with the province of Ontario to deliver the plan. Ontario established a Drugs for Rare Diseases (DRD) Framework to review and evaluate DRDs based on the best available evidence. The New Brunswick DRD Plan includes drugs that have been evaluated through the Ontario DRD Framework. Requests for coverage for New Brunswick patients are assessed by Ontario Public Drug Programs’ external medical experts using the same clinical criteria.
The plan will consider requests for coverage of the following drugs for specific rare diseases:
1. Aldurazyme (laronidase) for the treatment of Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I)
2. Elaprase (idursulfase) for the treatment of Hunter's Syndrome
3. Ilaris (canakinumab) for the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS) - Muckle-Wells Syndrome (MWS) and Neonatal-Onset Multisystem Inflammatory Disease (NOMID) only.
4. Myozyme (alglucosidase alfa) for infantile/early and adult/late onset Pompe disease
5. Naglazyme (galsulfase) for the treatment of Mucopolysaccharidosis VI (MPS VI)
6. Zavesca (miglustat) for the treatment of Niemann Pick Type C (NPC)
Request forms may be obtained by calling 1-800-332-3692.